{
    "root": "69c87b29-2670-aa40-b36a-40df421adb14",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "eribulin mesylate",
    "value": "20250319",
    "ingredients": [
        {
            "name": "ERIBULIN MESYLATE",
            "code": "AV9U0660CW"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "eribulin mesylate injection microtubule inhibitor indicated treatment patients : metastatic breast cancer previously received least two chemotherapeutic regimens treatment metastatic disease . prior therapy included anthracycline taxane either adjuvant metastatic setting . ( 1.1 ) unresectable metastatic liposarcoma received prior anthracycline-containing regimen . ( 1.2 )",
    "contraindications": "administer 1.4 mg/m 2 intravenously 2 5 minutes days 1 8 21-day cycle . ( 2.1 ) reduce dose patients hepatic impairment moderate severe renal impairment . ( 2.1 ) mix drugs administer dextrose-containing solutions . ( 2.3 )",
    "warningsAndPrecautions": "ndc 60505-6235-0 eribulin mesylate injection : 1 mg/2 ml ( 0.5 mg/ml ) single-dose vial . discard unused portion . one vial per carton . eribulin mesylate injection clear , colorless solution . store 25°c ( 77°f ) ; excursions permitted 15° 30° c ( 59° 86° f ) . freeze refrigerate . store vials original cartons . eribulin mesylate injection cytotoxic . follow applicable special handling disposal procedures.¹",
    "adverseReactions": "none .",
    "indications_original": "Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 )",
    "contraindications_original": "Administer 1.4 mg/m 2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. ( 2.1 ) Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. ( 2.1 ) Do not mix with other drugs or administer with dextrose-containing solutions. ( 2.3 )",
    "warningsAndPrecautions_original": "NDC 60505-6235-0\n                  \n                  Eribulin Mesylate Injection : 1 mg/2 mL (0.5 mg/mL) single-dose vial. \n                  Discard unused portion. One vial per carton.\n                      Eribulin mesylate injection is a clear, colorless solution.\n                  \n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F). Do not freeze or refrigerate. Store the vials in their original cartons.\n                  \n                  Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹",
    "adverseReactions_original": "None."
}